Financial Position - As of December 31, 2024, the company had cash and cash in escrow of 152,021andaworkingcapitaldeficitof128,968[325] - As of December 31, 2024, the company had cash at bank of 152,021andnocashinescrow[332]−Theprincipalamountdueunderapromissorynotewas0 as of December 31, 2024, down from 217,614in2023[326]−Thecompanyhasapromissorynotewithaprincipalamountof0 as of December 31, 2024, down from 217,614in2023[333]−Thecompanyhasatemporaryadvanceof129,759 from the sponsor as of December 31, 2024, compared to 490,000in2023[334]BusinessCombination−ThecompanyenteredintoabusinesscombinationagreementwithMaiusPharmaceuticalCo.,Ltd.onOctober22,2024[320]−ThecompanyhasadeadlinetocompleteitsinitialbusinesscombinationbyApril23,2025,withthepossibilityofextendingitupto27months[317]−Thecompanymayextendthedeadlineforcompletingabusinesscombinationupto27monthsfromtheIPOclosingdate,withthelatestdeadlinesetforApril23,2025[327]−Ifthecompanyfailstocompleteabusinesscombinationbythedeadline,itwilltriggeranautomaticwindingupandliquidationprocess[328]−Thecompanyisrequiredtosecureatleast10,000,000 from third-party investors as part of the business combination agreement[324] - The first monthly extension fee of 207,000wasdepositedintotheTrustAccounttoextendthedeadlineforthebusinesscombination[317]RevenueandIncome−Thecompanyreportedanetincomeof2,265,806 for the year ended December 31, 2024[325] - For the year ended December 31, 2024, the company reported a net income of 2,265,806,primarilyfromdividendincomeof3,000,071, offset by operating costs of 734,291[337]−Thecompanyhasnotgeneratedanyrevenuestodateandhasfocusedonpreparingforitsinitialpublicoffering[312]InitialPublicOffering−ThecompanycompleteditsinitialpublicofferingonFebruary23,2024,raisinggrossproceedsof69,000,000 from the sale of 6,900,000 units at 10.00perunit[329]−Atotalof69,345,000 from the IPO and private placement was deposited in the trust account, intended for the initial business combination[330] - The underwriters are entitled to a cash underwriting discount of 2.5% of the gross proceeds of the IPO, amounting to 1,725,000,upontheclosingoftheinitialbusinesscombination[339]OperatingActivities−Thecompanyincurredcashusedinoperatingactivitiesof686,691 for the year ended December 31, 2024[331] - The company may incur significant costs in pursuing its initial business combination, and there is no assurance of success in raising capital[314] Share Redemption - A total of 1,868,367 ordinary shares were redeemed for cash at approximately 10.61pershare,totalingaround19,821,345[318]